X T L Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd (ticker XTLB) is a very small-cap biopharmaceutical company with a market capitalisation of about $11.81 million. It operates in the pharmaceutical/biotech space, typically focusing on developing therapeutic approaches and drug-delivery technologies. As a small, early-stage company it can be highly dependent on the progress of a limited number of projects, regulatory milestones, partnership deals and access to capital. That profile usually brings elevated volatility and the possibility of dilution if additional fundraising is required. Liquidity in the shares may be low, which can magnify price moves. For investors interested in XTLB, it’s important to review the company’s latest filings, clinical or product development updates, and financing plans. This summary is educational only and not personalised investment advice; prospective investors should consider their risk tolerance and consult a financial adviser if unsure.
Stock Performance Snapshot
Financial Health
X T L Biopharmaceuticals is generating modest revenue and cash flow, but faces low profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring XTLB
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage catalysts
Share moves may hinge on trial data, regulatory milestones or partnerships; these events can create sharp gains or losses, so expect volatility.
Technology focus
If the company advances novel delivery or therapeutic technology it could add value, though technical and regulatory hurdles remain significant.
Capital and partners
Funding rounds or licensing deals can de‑risk programmes or dilute equity; monitor announcements and cash runway closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
